Does a single intramuscular injection of nirsevimab (Beyfortus) reduce the likelihood of hospitalization for respiratory syncytial virus (RSV) in infants who do not meet criteria for receiving palivizumab?

Palivizumab is a monoclonal antibody given as a monthly injection during the winter to infants at high risk of RSV complications. A large industry-sponsored, randomized controlled trial showed that a single intramuscular dose of nirsevimab administered to average-risk infants during the winter reduced the likelihood of hospitalization due to RSV. Nirsevimab is less expensive than palivizumab and requires only a single dose.

Read more: Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization Due to RSV in Average-Risk Infants During First Year of Life [POEMs]; May 2024

What are the main benefits of testosterone replacement therapy for male hypogonadism?

Testosterone replacement therapy for male hypogonadism leads to modest improvements in sexual function and depressive symptoms. Patients with heart disease or high cardiovascular risk should be counseled that, despite mixed evidence, recent data show that testosterone replacement therapy does not appear to increase the risk of myocardial infarction, stroke, or cardiovascular death.